Shows
PETRI DISH PERSPECTIVES: BIOTECH UNLEASHEDEpisode 11: GenentechSend us a text🧬 From VC to Blockbusters: The Genentech Story In Episode 11 of Petri Dish Perspectives: Biotech Unleashed, host Manead dives into the legendary rise of Genentech, the startup that sparked the biotech revolution. From its humble beginnings in a borrowed lab to pioneering insulin, tPA, Herceptin, and more, learn how Genentech turned recombinant DNA into real-world cures. Discover the bold VC bets, game-changing antibodies, and the Roche acquisition that preserved its science-first culture. A must-listen for biotech nerds and curious minds alike!🎧 #Genentech #BiotechPodcast #Herceptin #Avastin #Rituxan #RecombinantDNA #OncologyInnovation #PetriDishPerspectives #Health...2025-07-1026 min
200: Tech Tales FoundFrom DNA to Life-Saving Miracles: The Genentech RevolutionGenentech's story begins in 1976 with a groundbreaking scientific idea and an ambitious vision. Co-founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer, the company pioneered recombinant DNA technology—essentially allowing scientists to edit genetic code like a recipe book, inserting human genes into bacteria to produce life-saving proteins. Their first major success came in 1978 with synthetic human insulin, offering a safer, more scalable alternative to animal-derived insulin and transforming diabetes treatment. This breakthrough proved that biotechnology could move from theory to real-world impact. In 1980, Genentech became the first biotech company to go public, raising $35 million and si...2025-06-2317 min
WPTF Morning NewsLaura Gunter with NC Life Sciences on Genentech facility announcement Genentech has chosen North Carolina to open a Manufacturing plant in holly springs, this is a 700 million dollar invest for Genetech and hopes to bolster biotechnology and the economy of the area. Laura Gunter with NC Life Sciences speaks to Tony Riggsbee about the impact and future plans regarding this announcement. 2025-05-1405 min
US News DailyGenentech Invests in NC Facility, Allison Riggs Wins Supreme Court Race, Drone Captures Armed Boys Standoff, ChiefsAholic Sentenced to 32 Years, and more...(0:10): Genentech Invests $700M in Holly Springs Facility, Creating 420 Jobs and Boosting NC Economy(2:43): Allison Riggs Wins Contentious NC Supreme Court Race, Pledges to Uphold Voting Rights(5:06): Drone Footage Captures Tense Standoff: Armed Boys, 7 and 9, Highlight Urgent Gun Safety Concerns(7:02): 'ChiefsAholic' Sentenced to 32 Years for Multi-State Bank Robbery Spree(9:09): AG Coalition Demands Action from WeChat for Alleged Fentanyl Trafficking RoleTo subscribe visit https://www.brief.news.For more updates in your inbox each morning visit www.brief.news.
Image credit: WSOC TV2025-05-1411 min
The Big ImpressionGenentech’s Erica Taylor on how healthcare brands became mainstream post-CovidGenentech VP, CMO Erica Taylor joins The Current Podcast to share her unique journey from immunology to biotech marketing, and the evolving role of biotech brands in mainstream media. Episode TranscriptPlease note, this transcript may contain minor inconsistencies compared to the episode audio.Kat Vesce (00:00):I'm Kat Vesce. And I'm Ilyse Liffreing and welcome to this edition of The Current Podcast. In honor of International Women's Day and Women's Month, we're spotlighting trailblazing women in marketing at this year's South by Southwest.Ilyse Liffreing (00:16):For...2025-03-2027 min
It's Bigger than BiotechDecoding Biotech Careers: Christian Chung’s Path to Genentech and BeyondIn this episode of It's Bigger Than Biotech, Hriday and Vishnu sit down with Christian Chung, a recent USC graduate and Process Development Intern at Genentech. Christian shares his journey through academia, where he earned a B.S. in Human Biology and a Master’s in Stem Cell Biology, and his transition into the pharmaceutical industry. From co-founding Revilico to pioneering AI-driven drug repurposing solutions, Christian offers invaluable insights into big pharma recruitment, the importance of research, and the evolving role of automation in pharma-tech operations. Tune in for a fascinating conversation on curiosity, career growth, and the future of...2025-02-1242 min
Eyewire News: The PodcastFDA Approves Genentech's Susvimo Ocular Implant for DMEThe FDA approves a label expansion for Genentech’s Susvimo implant; Iantrek completes the first commercial cases of its C.Rex micro-interventional system; and there are several executive leadership announcements made in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoices2025-02-0505 min
Let's Talk QualityAndrea Goddard on her journey from 'the graveyard shift' to Chief Quality Officer at Genentech.In today's episode, I'm joined by Andrea Goddard, former Chief Quality Officer at Genentech. Andrea shares her career journey and insights into quality leadership. She started in biotech manufacturing and transitioned into quality after a conversation with her boss! Andrea emphasizes the importance of building strong relationships between quality and other departments within an organization. She discusses the challenges and rewards of working in a global role, including managing different time zones and cultures. We cover:Building strong relationships between quality and other departments.Managing different time zones and cultures.The importance of respect...2024-11-0636 min
The Readout Loud324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drugOur colleague Jonathan Wosen joins us to discuss the recent setbacks and wins in oncology R&D, including Genentech's decision to shut down its cancer immunology group, and the global ambitions of Akeso, the Chinese biotech behind Summit Therapeutics’ recent positive results. We also chat about the latest news in the life sciences, including Pfizer’s sudden announcement to pull its sickle cell drug and the imminent approval of Bristol Myers Squibb’s schizophrenia treatment.2024-09-2632 min
Off Script: A Pharma Manufacturing PodcastGenentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly]Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — Genentech's oral weight loss drug shows promise
The bad — FDA denies accelerated approval for Agenus' cancer drug
The ugly — Orexo's opioid overdose drug rejected again
2024-07-2203 min
The Corporate Real Estate InsiderE39: Genentech’s Head of Real Estate and Workplace Effectiveness, Sara Andersen(0:00) Opening(0:33) How does workplace effectiveness relate to the director of real estate role?(10:21) How does Genentech make real estate decisions and what is the process?(22:04) How has the director of real estate role changed?(36:19) Genentech’s strategy to future-proof their sites(44:47) Sara’s take on remote work(51:48) Mentorship in CRE(57:53) ClosingTo learn more about the podcast, please visit www.thecreinsider.com or email podcast@thecreinsider.com to get in touch with us directly.2024-07-1757 min
The Real Chemistry PodcastCannesplaining Healthcare: Emphasizing the Importance of Creativity in Healthcare with Genentech Chief Marketing Officer, Dr. Erica TaylorLive from the 2024 Cannes Lions International Festival of Creativity, join us as we explore the intersection of creativity, marketing and healthcare during our latest Cannesplaining Healthcare podcast episode featuring Genentech Chief Marketing Officer (CMO) Dr. Erica Taylor, 21GRAMS Managing Founder & Real Chemistry Chief Creative Officer Frank Mazzola, and 21GRAMS Executive Creative Director Lauren Pollina. Discover how Genentech is modernizing marketing in the pharmaceutical industry and gain insights into the importance of creativity, the challenge of incorporating levity into health marketing and the value of early regulatory involvement in marketing campaigns. Learn from Dr. Erica Taylor's unique journey to her...2024-06-2740 minThe Real Chemistry PodcastCannesplaining Healthcare: Emphasizing the Importance of Creativity in Healthcare with Genentech Chief Marketing Officer, Dr. Erica TaylorLive from the 2024 Cannes Lions International Festival of Creativity, join us as we explore the intersection of creativity, marketing and healthcare during our latest Cannesplaining Healthcare podcast episode featuring Genentech Chief Marketing Officer (CMO) Dr. Erica Taylor, 21GRAMS Managing Founder & Real Chemistry Chief Creative Officer Frank Mazzola, and 21GRAMS Executive Creative Director Lauren Pollina. Discover how Genentech is modernizing marketing in the pharmaceutical industry and gain insights into the importance of creativity, the challenge of incorporating levity into health marketing and the value of early regulatory involvement in marketing campaigns. Learn from Dr. Erica Taylor's unique journey to her...2024-06-2740 min
Two Scientists Walk Into a BarS5E04: Engineering Therapeutic AntibodiesAntibodies are proteins produced by our immune system that neutralize or help destroy abnormal cells and foreign agents, like bacteria and viruses. However, their utility extends beyond our bodies’ defense system. Antibodies can also be engineered in the lab to be used as therapies. Today, over 170 antibodies have been approved as medicines to treat a wide range of diseases including cancers, autoimmune diseases, infectious diseases and more. In this episode, co-host Maria Wilson chats with guests Yan Wu, VP and Senior Fellow, Antibody Engineering, and Paul Carter, Genentech Fellow, Antibody Engineering, to discuss all things antibodies! Learn about the history of...2024-06-2629 minOff Script: A Pharma Manufacturing PodcastGSK antibiotic hits phase 3 goals, Genentech-Adaptimmune collab ends, Par Pharma recall [The good, the bad, the ugly]Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — GSK antibiotic hits phase 3 goals in gonorrhea
The bad — Genentech ends $3B Adaptimmune T-cell collab
The ugly — Par Pharmaceutical recalls Treprostinil injection for potential contamination
2024-04-2204 min
PeerView Immunology & Transplantation CME/CNE/CPE Video PodcastGhassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted ApproachesThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAU865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches In support of improving patient care, this activity has been...2024-02-131h 30
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastGhassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted ApproachesThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAU865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches In support of improving patient care, this activity has been...2024-02-131h 30
PeerView Internal Medicine CME/CNE/CPE Audio PodcastGhassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted ApproachesThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAU865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches In support of improving patient care, this activity has been...2024-02-131h 30
PeerView Immunology & Transplantation CME/CNE/CPE Audio PodcastGhassan Abou-Alfa, MD, MBA - Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted ApproachesThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/AAU865. CME/MOC/AAPA/IPCE credit will be available until February 18, 2025.Calibrating Care Across the HCC Continuum: Guidance on Delivering Effective Care With Modern Immunotherapy and Targeted Approaches In support of improving patient care, this activity has been...2024-02-131h 30
The Mind Body Business ShowEp 277:Channel Operations & Genentech Brandon Bakhtiar The Mind Body Business ShowBrandon holds a bachelor’s of science in microbiology & molecular genetics and a advanced degree from UC Davis in Comparative Pathology. After taking & not passing the patent bar Brandon was starting to study for a 2nd exam date when he was offered a position as a personal trainer at a high end fitness club in San Francisco where he first learned the principles of reciprocal inhibition and started gaining experience. After going independent and making a living for 12 years in San Francisco as a self employed personal trainer, Brandon was hired by Genentech where he worked for 3 years before fo...2024-01-291h 00
Something About ScienceLive Cell Imaging in Drug Discovery: In Conversation With GenentechIn this episode, hosts Megan and Danielle chat with Nont Kosaisawe a Senior Systems Specialist at Genentech about the technologies and techniques being used to uncover the molecular intricacies of cell decisions. As pioneers in the biotechnology industry and members of the Roche Group, Genentech is determined to revolutionize how we treat some of the most complex diseases. Already, Genentech has developed the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis.Discover how live cell imaging can offer detailed insights into cell behaviour in real-time, and what this means f...2023-11-2238 min
The CMO PodcastCotopaxi, Genentech, and Toyota Motor North America | CMO Panel at Deloitte University Next Generation CMO AcademyHow do you prepare to join the C-Suite after years of working as a marketing leader? Jim wraps up the final episode from the 2023 Deloitte University Next Generation CMO Academy with a roundtable panel discussion featuring Brad Hiranaga (Chief Brand Officer of Cotopaxi), Erica Taylor (Vice President and Chief Marketing Officer of Genentech), and Lisa Materazzo (Group Vice President of Marketing at Toyota Motor North America). Brad Hiranaga is a returning guest to the podcast. He spoke to Jim in 2021 as Chief Marketing Officer at General Mills, where he spent 18 years. Now a year into his new...2023-11-1549 min
The Internship ShowGenentech Program OverviewOn this episode of The Internship Show, we're joined by Demetria Johnson from Genentech. She discusses their internship program, how their Diversity & Inclusion initiatives are tied to it, and more. 2023-09-2609 min
Girl Power GurusDr. Aviv Regev - Computational Biologist and Head of Genentech research and early developmentFor our latest episode we are talking with Dr. Aviv Regev. Dr. Regev is the head of Genentech Research and Early Development. Prior to Genentech, Regev served as Chair of the Faculty and Core Member at the Broad Institute of MIT and Harvard, and as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas.2023-09-1450 min
BioCentury This WeekEp. 188 – Pharma deals; Plus: Genentech, Leerink ConversationsAn analysis of pharma deal trends over the past year shows a focus on first-in-class assets with autoimmune diseases being a major focus of interest. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the deal trends mean for prospective pharma partners and whether the expected focus on late-stage products, and a material increase in valuation for late-stage programs, is supported by the data. BioCentury’s editors also talk about a recent conversation with Genentech Inc. CEO Alexander Hardy, and his perspective on how the Inflation Reduction Act (IRA) may impact future decision-making on drug development for...2023-07-3125 min
OIS Podcast | Ophthalmology's leading PodcastFrom Lab Learning to Machine Learning, with Daniela Ferrara, GenentechDaniela Ferrara, Principal Medical Director at Genentech, calls her extensive medical training in Brazil her “north star.” Yet, she was frustrated by the limitations of clinical practice. “Having patients go blind under my watch, I realized I would never defeat blindness through practice,” she said.She turned her attention to clinical research, where her work could potentially improve the health of many rather than the few. More recently, with a focus on applying artificial intelligence and machine learning to multimodal imaging, her work could impact an even broader population sooner.With podcast h...2023-07-0746 min
The MM+M PodcastMM+M Podcast 5.17.23: ‘No quick solution’: Genentech’s Highsmith talks progress, challenges on road to DE&IQuita Highsmith tells Jack O’Brien about the “long journey” toward addressing the impact of health inequities, and how Genentech is fostering more diversity in society through steady investments and partnerships. Lecia Bushak explains why the DEA is extending pandemic-era telehealth flexibility for accessing controlled substances, as well as Biden’s nominee for head of the NIH. And Jack cues up three more trending topics: Bo Jackson’s curious case of hiccups, whether an AI-powered “virtual girlfriend” can cure loneliness, and how potentially risky “free births” are proliferating on TikTok. Follow us on twitter: @MMMnewswww.mmm-online...2023-05-1733 min
Talking TechniciansS03-E09 Jose works at GenentechJose works at Genentech. Jose grew up in the Bay Area and went from working in restaurants to a career in biotechnology. Hear about how Jose enrolled in a community college program, completed an internship and now has a career at one of the biggest biotech companies. Jose talks about what he is most passionate about at work and how you can work towards your dream career too.The Talking Technicians podcast is produced by MNT-EC, the Micro Nano Technology Education Center, through financial support from the National Science Foundation's Advanced...2023-05-0116 min
Audio Articles from The Stanford DailyGenentech discloses unreported research misconduct in Stanford President’s lab, says it did not find ‘intentional wrongdoing’ in 2009 paperRead the article here: https://stanforddaily.com/2023/04/06/stanford-president-research-misconduct-concerns-genentech2023-04-0700 min
The Johns Hopkins #100 Alumni Voices ProjectDr. Yenny Webb Vargas, PhD in Biostatistics | Principal Statistical Scientist at GenentechIn this episode, we discuss what led Yenny to pursue her PhD in Biostatistics at Johns Hopkins University, the importance of finding community and support systems to cultivate wellbeing and success, and the impact of her work as a nonclinical biostatistician at Genentech. Hosted by Brooklyn ArroyoTo connect with Yenny and to learn more about her story, visit her page on the PHutures #100AlumniVoices Project website.2023-03-1429 min
The Brand InsiderEp. 78 with Erica Taylor, Genentech's CMOIn this episode, Steve chats with Genentech's CMO, Erica Taylor.2023-02-0920 min
Dimensions of DiversityDriven from the Top: How Genentech is Advancing D&I in Life SciencesOn this episode of Dimensions of Diversity, host Lloyd Freeman speaks with Jayson Johnson, Head of D&I Business Partnering and Learning & Development. The COVID-19 pandemic shined a light on the life sciences industry and we learned that advancing D&I in life sciences could advance life saving solutions. Lloyd and Jayson explore Genentech's commitment to advancing D&I. As a biotechnology leader, Jayson Johnson drives strategies and bold actions that embed diversity, equity and inclusion throughout Genentech. At Genentech, D&I means fostering belonging within our own walls, advancing inclusive research and health equity in our industry...2022-12-0122 min
Science Metaverse PodcastEP 40: Exploring structural data landscapes for drug discovery with Dr. Seth Harris from GenentechIn this webinar, Dr. Seth Harris, Director of Computational Structural Biology & Senior Principal Scientist at Genentech, talks about GYST, the XR-integrated system developed by Genentech to efficiently manage large structural datasets. At Genentech, the in-house GYST platform is used to explore annotated structural datasets and rapidly get insights from large amounts of structural information.GYST integrates Nanome in its systems and allows researchers to access information, and manipulate and visualize data in the immersive virtual reality environment. During the webinar, Dr. Harris will go over the collaboration between scientists at Genentech and the Nanome team t...2022-11-1348 min
The Reboot Chronicles with Dean DeBiaseThe Science and AI of Silicon Valley Leadership - Genentech CEO Alexander HardyPioneering the biotech industry back in the 70’s, Silicon Valley based Genentech is one of the world’s most innovative pharmaceutical companies and a leader in breakthrough lifesaving drugs, treatments, and technologies. Now part of Roche the combined entities have tens of thousands of patents and employ over 100,000 people in 100 countries who delivered over $68 B in revenue last year.
Their transformational discoveries include the first targeted antibody for cancer, and the first medicine for primary progressive multiple sclerosis. Early 2022 saw Genentech get FDA approval in ophthalmology, with a bispecific antibody for two leading causes of vision loss; under...2022-10-1233 min
AHLA's Speaking of Health LawCareer Journeys of Latino/Latina Health Law Leaders: Sarina Rivera, Assistant General Counsel, GenentechIn honor of National Hispanic Heritage Month, AHLA has partnered with the Hispanic National Bar Association to present this three-part series highlighting the career journeys of Latino/Latina health law leaders. In the first episode, Gelvina Rodriguez Stevenson, Vice President, General Counsel, The Wistar Institute, and Esteban Rodriguez, Counsel, O’Melveny & Myers LLP, speak with Sarina Rivera, Assistant General Counsel, Genentech. In her role, Sarina has provided strategic health care and FDA regulatory counseling to global and U.S. R&D organizations, and she currently supports Genentech’s pharmaceutical technical group and is active in the organization’s diversity and in...2022-10-0331 min
Life Science TodayBluebird, Endo & Pharmacies, Genentech + Jemincare, Merck + OrnaGene therapy approval, opioid costs continue, a $650M deal, and a $3.5B RNA partnership. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesBluebirdEndo & PharmaciesGenentech + JemincareMerck + OrnaAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today...2022-08-2308 min
Two Scientists Walk Into a BarS4E07: Representation Matters: Inclusivity in Clinical TrialsBecause disease outcomes and responses to treatment can vary across populations, clinical research must include patients who are racially, ethnically and gender representative of those who experience health conditions. Scientists are pioneering new ways of achieving inclusive and diverse clinical trials to generate clear results and reveal insights when evaluating new medicines. Co-host Maria Wilson sits down with Nicole Richie, Global Head of Health Equity and Population Science, and Jenn Pangilinan, Vice President, Genentech Research and Early Development (gRED) Clinical Operations, to discuss the nuances of human biological difference and how we can take a more thoughtful approach to inclusivity...2022-08-1639 min
Health Professional Radio - PodcastGenentech - The State of Diversity, Inclusion, and Progress in BiotechGenentech - The State of Diversity, Inclusion, and Progress in Biotech by Vertical Internet Media2022-06-0110 min
AAD's Dialogues in DermatologyBonus: Diagnosing Basal Cell Carcinoma - What's Next (Sponsored by Genentech)Vishal Patel, MD, FAAD and Anthony Rossi, MD, FAAD interviewed by Brad Glick, DO, MPH, FAADThis episode has been sponsored by Genentech, a member of the Roche Group.View episode transcript2022-05-1300 minAAD's Dialogues in DermatologyBonus: Nonsurgical Treatment of Basal Cell Carcinoma (Sponsored by Genentech)Scott Dinehart, MD interviewed by Steven Chen, MD, MPH, FAADThis episode has been sponsored by Genentech, a member of the Roche Group.View episode transcript2022-04-2200 minLife Science TodayGenentech, Immunocore, Biogen, Eli Lilly, TenSixteenBispecific antibodies, ocular oncology, Biogen sells, Lilly Builds, and the treatment of a lifetimeFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesGenentechImmunocoreBiogenEli LillyTenSixteenAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs...2022-02-0107 min
Digital ConversationsGenentech’s Rapid Innovation Strategy to Deliver Exceptional Clinical Trial ExperiencesGenentech US Medical Affairs is involved in hundreds of concurrent clinical trials that involve a spectrum of participants and investigators. The world of clinical trials and therapy development has been evolving and now COVID-19 is forcing the industry to innovate in different ways as it deals with labor shortages, supply chain disruptions, and a new virtual-first patient engagement environment. Nik Kolatkar, Vice President, Scientific Operations, US Medical Affairs at Genentech sat down with Greg Kefer to discuss his vision for reimagining the way trials are executed. In order to meet modern consumer expectations, Genentech is leveraging advanced...2022-01-1223 min
Northwestern IntersectionsHow Northwestern Shaped the Lives and Careers of the 2020–21 Northwestern Alumni Medalists, with Senior Vice President of Research–Biology at Genentech, Andrew C. Chan ’80, ’80 MSSince 1932, the Northwestern Alumni Medal has celebrated alumni who have had a transformative impact on their fields, who have performed exemplary volunteer service to society, or who have demonstrated an outstanding record of service and support to the University. In this special episode of Northwestern Intersections, we will hear insights from this year’s recipients of the Northwestern Alumni Association’s highest honor: Judy Belk ’75, Andrew C. Chan ’80, ’80 MS, Christopher B. Combe ’70 (’99, ’09 P), and Gordon Segal ’60 (’93 P). In episode 106b we will hear from Andrew C. Chan, senior vice president of research–biology at Genentech, a biotechnology company that works to...2021-12-1720 min
Konnecting KeelhaulersAlum: Jacob Lassila ’18 | Senior Utility Plant Operator, GenentechJacob Lassila, FET class of 2018, sits down with Ryan Rodriguez to discuss his career with Genentech. They discuss his path from summer intern with Genentech while attending Cal Maritime to his current role Senior Utility Plant Operator with the company, with Jacob highlighting the need to be willing and active in adapting to changing roles and expectations even while working at the same company. Jacob also reflects on his time at Cal Maritime and gives some advice to current cadets about how to handle the many responsibilities they on campus.2021-11-1746 min
Xtalks Life Science PodcastFDA Authorizes Pfizer COVID-19 Vaccine for Children 5 to 11 + Genentech’s Drug Delivery System for Macular DegenerationIn this episode, Ayesha discusses the FDA’s authorization of Pfizer/BioNTech’s COVID-19 vaccine for children between five and 11 years of age. The authorization was based on trial data that showed the vaccine was safe, well-tolerated and induced robust immune responses among children in this age group; side effects were generally mild to moderate. Amid concerns of the rare adverse event of myocarditis in children and adolescents following vaccination with mRNA vaccines, the FDA conducted its own benefit-risk analysis that showed the benefit of vaccination outweighs the risk of myocarditis. The editorial team discussed the positive trial data, the...2021-11-0334 min
Foundation Fighting BlindnessNews | FDA Approves Genentech’s Susvimo for Treating Wet AMDThe US Food & Drug Administration (FDA) has approved Susvimo, Genentech’s port delivery system (PDS) with ranibizumab, for the treatment of wet age-related macular degeneration (AMD). The PDS, a refillable capsule the size of a rice grain, provides continual release of ranibizumab, a protein that blocks the growth of vision-robbing, leaky blood vessels which are the hallmark of wet AMD. The PDS is implanted at the surface of the eye during a one-time, outpatient, surgical procedure. The PDS may be refilled as infrequently as twice a year. Susvimo will be available to patients in the coming months.2021-10-2503 min
Occupation StationFrom ACPPHS to GenentechWhile his work is always changing to adapt to industry needs, a typical day for ACPHS grad Salah El-Saheb involves working with biostatisticians, data scientists and clinical operations. Salah is Executive Director, Evidence Generation Leader at Genentech and his goal is to find more efficient and effective ways to conduct drug trials to bring therapies out to patients as quickly as possible. While the work is complicated, his underlying desire is ultimately to get help to those who are sick with as little discomfort on their part as possible. His skill at partnering with medical colleagues to benefit patients comes...2021-10-0814 min
Enjoy This Vivid Full Audiobook And Feel The Difference.Genentech by Sally Smith HughesPlease visithttps://thebookvoice.com/podcasts/2/audible/16324to listen full audiobooks.
Title: Genentech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: mp3
Length: 7 hrs and 12 mins
Release date: 09-28-21
Ratings: 4 out of 5 stars, 33 ratings
Genres: Computer Science
Publisher's Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological...2021-09-287h 12
Discover Into A Unforgettable Full Audiobook During Your Workout.Genentech: The Beginnings of Biotech by Sally Smith HughesPlease visithttps://thebookvoice.com/podcasts/1/audiobook/534808to listen full audiobooks.
Title: Genentech: The Beginnings of Biotech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: Unabridged Audiobook
Length: 7 hours 12 minutes
Release date: September 28, 2021
Ratings: Ratings of Book: 5 of Total 2
Ratings of Narrator: 5 of Total 1
Genres: Business & Career Development
Publisher's Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading...2021-09-287h 12Get Lost In An Sensational Full Audiobook And Elevate Your Mindset.Genentech: The Beginnings of Biotech by Sally Smith HughesPlease visithttps://thebookvoice.com/podcasts/1/audiobook/534808to listen full audiobooks.
Title: Genentech: The Beginnings of Biotech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: Unabridged Audiobook
Length: 7 hours 12 minutes
Release date: September 28, 2021
Ratings: Ratings of Book: 5 of Total 2
Ratings of Narrator: 5 of Total 1
Genres: Biology & Chemistry
Publisher's Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming...2021-09-287h 12Enjoy Amazing Full Audiobooks in Non-Fiction, Biology & ChemistryGenentech: The Beginnings of Biotech by Sally Smith HughesPlease visithttps://thebookvoice.com/podcasts/1/audiobook/534808to listen full audiobooks.
Title: Genentech: The Beginnings of Biotech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: Unabridged Audiobook
Length: 7 hours 12 minutes
Release date: September 28, 2021
Ratings: Ratings of Book: 5 of Total 2
Ratings of Narrator: 5 of Total 1
Genres: Biology & Chemistry
Publisher's Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming...2021-09-287h 12
Enjoy Amazing Full Audiobooks in Non-Fiction, Biology & ChemistryGenentech: The Beginnings of Biotech by Sally Smith HughesPlease visit https://thebookvoice.com/podcasts/1/audiobook/534808 to listen full audiobooks. Title: Genentech: The Beginnings of Biotech Author: Sally Smith Hughes Narrator: Suzie Althens Format: Unabridged Audiobook Length: 7 hours 12 minutes Release date: September 28, 2021 Ratings: Ratings of Book: 5 of Total 2 Ratings of Narrator: 5 of Total 1 Genres: Biology & Chemistry Publisher's Summary: In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading...2021-09-2830 minDiscover This Ground-Breaking Full Audiobook — Perfect Between Meetings.Genentech by Sally Smith HughesPlease visithttps://thebookvoice.com/podcasts/2/audible/16324to listen full audiobooks.
Title: Genentech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: mp3
Length: 7 hrs and 12 mins
Release date: 09-28-21
Ratings: 4 out of 5 stars, 33 ratings
Genres: Computer Science
Publisher's Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological...2021-09-287h 12
Listen and Let Your Mind Roam Free With Full AudiobookGenentech: The Beginnings of Biotech Audiobook by Sally Smith HughesListen to this audiobook in full for free onhttps://hotaudiobook.com/freeID: 534808
Title: Genentech: The Beginnings of Biotech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: Unabridged
Length: 07:12:23
Language: English
Release date: 09-28-21
Publisher: Tantor Media
Genres: Business & Economics, Science & Technology, Biology & Chemistry, Business Development
Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at...2021-09-287h 12Get Lost In The Most Binge-Worthy Full Audiobook Today!Genentech by Sally Smith HughesPlease visithttps://thebookvoice.com/podcasts/2/audible/16324to listen full audiobooks.
Title: Genentech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: mp3
Length: 7 hrs and 12 mins
Release date: 09-28-21
Ratings: 4 out of 5 stars, 33 ratings
Genres: Computer Science
Publisher's Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological...2021-09-287h 12Access Unmissable Full Audiobooks in Business & Economics, Business & Career DevelopmentGenentech: The Beginnings of Biotech by Sally Smith HughesPlease visithttps://thebookvoice.com/podcasts/1/audiobook/534808to listen full audiobooks.
Title: Genentech: The Beginnings of Biotech
Author: Sally Smith Hughes
Narrator: Suzie Althens
Format: Unabridged Audiobook
Length: 7 hours 12 minutes
Release date: September 28, 2021
Ratings: Ratings of Book: 5 of Total 2
Ratings of Narrator: 5 of Total 1
Genres: Business & Career Development
Publisher's Summary:
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading...2021-09-287h 12
Access Unmissable Full Audiobooks in Business & Economics, Business & Career DevelopmentGenentech: The Beginnings of Biotech by Sally Smith HughesPlease visit https://thebookvoice.com/podcasts/1/audiobook/534808 to listen full audiobooks. Title: Genentech: The Beginnings of Biotech Author: Sally Smith Hughes Narrator: Suzie Althens Format: Unabridged Audiobook Length: 7 hours 12 minutes Release date: September 28, 2021 Ratings: Ratings of Book: 5 of Total 2 Ratings of Narrator: 5 of Total 1 Genres: Business & Career Development Publisher's Summary: In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of...2021-09-2830 min
Being Human Is Good For Business LeadersEmpathetic Leadership Underpins Genentech’s Growth & SuccessIn this episode of the Being Human is Good For Business Podcast we talk to a leader at the forefront of the biotech industry, Genentech’s Vice President of Litigation, Mary Riley. In this interview, Mary shares with us how leading with empathy not only improved her team’s dynamics, but it also led to major breakthroughs for the business too. “Our group had existed for a number of years and thought they knew each other well,” explains Mary. “But it turned out they didn't actually know each other as well as they had thought. And as a res...2021-07-0832 min
Leaders in Pharmaceutical Business Intelligence (LPBI) GroupAllon Klein, Harvard Medical School, and Aviv Regev, Genentech, Recipients of National Academy of Sciences James Prize in Science and Technology Integration 2021 AwardThis episode is also available as a blog post: http://pharmaceuticalintelligence.com/2021/01/19/allon-klein-harvard-medical-school-and-aviv-regev-genentech-recipients-of-national-academy-of-sciences-james-prize-in-science-and-technology-integration-2021-award/2021-07-0603 min
科化未來EP1 – 基因工程藥物的先行者 GenentechGenentech這間公司於1976年於South San Francisco 創立，而在2009年被知名的傳統大藥廠Roche以468億美金的價錢收購，現在是在Roche旗下的一個子集團。在1982年的時候，Genetech所推出的第一個產品就是人工合成的胰島素，也是第一個被與許上市的基因工程藥品，可以說是打響了基因工程時代的先行者，就讓我們一起認識這間公司吧！2021-07-0106 min
Digital ConversationsHow Genentech is Innovating to Improve Diversity and Inclusion in Clinical TrialsThe race to develop a COVID-19 vaccine shined a light on an issue that has challenged the pharmaceutical industry for years. Underrepresented minority communities are often disproportionately impacted by diseases, yet those groups are usually underrepresented in the clinical trials that are designed to assess the effectiveness of drugs that they need. As one of the world’s largest biotechnology companies, Genentech is tapping advanced mobile technology to help increase the diversity of trial participants and improve the experience. In this episode of Digital Conversations, Nik Kolatkar, VP of Evidence Generation, US Medical Affairs at Genentech, joined Gr...2021-06-1426 min
Theory and PracticeGenentech’s Aviv Regev on the Promise of Single Cell GenomicsIt's rare to meet a true visionary, someone who sees where the world can go before anyone else sees it. And it's even rarer to meet someone who not only recognizes the opportunity, but also has the conviction and energy to make it a reality. For us, the person who most exemplifies these characteristics is Dr. Aviv Regev, who leads Genentech's Research and Early Development (gRED) team.Human genetics has had a transformative impact on drug development. Single cell genomics is at a similar place to where human genetics was ten years ago, and I can't imagine a...2021-06-0346 min
Lion LegacyClifton Tay, Head of University Talent Acquisition + Strategy - Genentech (#12)2003 Penn State graduate Clifton Tay has worked for some of the world's most exciting tech companies - GE, Facebook, Uber, Zillow and now Genentech. In this episode, Clifton shares his work recruiting talent for these companies, his perspectives on the future of work and more!Jump right in:(4:06) - Getting into the talent acquisition field(5:45) - Moving from GE to Facebook(8:24) - The competition for talent(10:39) - Joining Genentech(11:53) - Differentiating yourself in the candidate pool(14:10) - Companies supporting employees(19:56...2021-04-0835 min
DTx Podcast with Eugene BorukhovichBuilding the Genentech of Digital TherapeuticsCorey McCann says he always wanted to name a company after a fruit, and when he and his team saw an opportunity to “pair” drugs and software to treat serious disease and improve patient outcomes, the name Pear Therapeutics was born.Of course, the other inspiration for the creation of Pear Therapeutics was Genentech, in that Corey and his team wanted to build something big and capitalize on the hundreds of opportunities they see to modify standards of efficacy with software solutions.Corey, Eugene, and Brian talk about Pear’s early foray into the digital therap...2021-03-3034 min
TCAST: The Future of Data & AIGenentech Making Steps for Humans and the PlanetIt came to our attention that we tend to point out all the bad stuff going on. Whether it be talking about how social media companies are selling your data, other companies skimming it off your activity, tracking your location, or governments trying to force their way into the blockchain economy we tend to focus too much on the negatives. While that is a natural tendency of human nature (the news has a saying – if it bleeds, it leads), there is plenty of good stuff going on as well. We at TARTLE think it’s our responsibility to make sure...2021-03-2614 min
REACH - A Podcast for Executive AssistantsFrom Working at the Bio-Pharma Behemoth Genentech to Scrappy Startup Grail: Everything You Need to Know About Being an Executive Assistant in BiotechIn this episode, Stacy Green, Senior Executive Assistant to the CEO of Grail, sheds light on the biotech industry from an EA’s perspective. She discusses everything from the challenges and rewards of the field, what it’s like to work with a bunch of scientists and PhDs and what to expect if you’re thinking of joining a biotech company, whether big or small. Prior to her role at Grail, a company committed to saving lives by detecting cancer early on when it has a better chance of being cured, Stacy worked as an EA at the biopharma behemo...2021-03-0141 min
Intel on AIGenentech: Biomedicine Meets AI – Intel on AI Season 2, Episode 15In this episode of Intel on AI guest Aviv Regev, Executive Vice President of Genentech Research and Early Development, talks with host Abigail Hing Wen, Intel AI Tech Evangelist and New York Times best-selling author, about biomedicine and artificial intelligence (AI). The two discuss Aviv’s work on circuitry in cells, the future of experimental biology, why increasing the diversity of data is key to creating algorithms that can find patterns in genomic variants, and how strengthening global networks will help society better prepare for the next pandemic. Hear more from Aviv in a special episode of Ge...2021-02-1143 minTwo Scientists Walk Into a BarS4E0: Studying the Symphony of CellsCells are the basic unit of life, with a remarkable ability to sense their environment, process information and adapt accordingly. With 37.2 trillion cells in the human body, there remains plenty for scientists to discover about how this symphony of cells is organized and works together. In this special episode, producer Wellington Bowler chats with Aviv Regev, Executive Vice President, Genentech Research and Early Development, to discuss her vision for the roles that single cell genomics and computational biology can play in not only forwarding our basic understanding of biology, but also in our ability to generate new insights about disease...2021-01-2636 min
Health Professional Radio - PodcastGenentech - Uniting Bay Area Communities in Addressing Childhood AdversityRajni Dronamraju, Senior Director, Charitable Giving Strategy at Genentech, discusses Genentech’s ongoing efforts to address the impact of trauma, stress and racism on the health and well-being of low-income kids and families across the Bay Area. She also discusses the recent launch of the All In For Kids multi-donor fund to unite Bay Area nonprofits, advocates and leaders in advancing solutions that address childhood adversity and trauma. Genentech seeded the fund with $5M. Listeners can learn more at The Resilience Effect.2021-01-1111 min
The Data PulseDesign for inference and massively parallel single cell -omics with Aviv Regev (Broad Institute -> Genentech)From single cells to international consortia and from striving despite fear to creating a "vector field" to inspire teams working in sync, Dr. Aviv Regev shares countless insights into how she has merged the worlds of computation and biomedicine, first at the Broad Institute and now at Genentech.
---
Support this podcast: https://anchor.fm/the-data-pulse/support2020-12-2348 min
The MM+M PodcastEpisode 73: Genentech's Quita HighsmithGenentech isn’t currently developing a SARS-CoV-2 vaccine or therapeutic, but the biotech has been conducting research that could bring insight to bear on the willingness among communities of color to engage in clinical trials for COVID-19 vaccines and treatments. Quita Highsmith, Genentech’s chief diversity officer, speaks about that, and the biotech’s own efforts to recruit and instill more trust among underserved and medically disenfranchised patients.2020-10-2826 min
The MM+M PodcastEpisode 73: Genentech's Quita HighsmithGenentech isn’t currently developing a SARS-CoV-2 vaccine or therapeutic, but the biotech has been conducting research that could bring insight to bear on the willingness among communities of color to engage in clinical trials for COVID-19 vaccines and treatments. Quita Highsmith, Genentech’s chief diversity officer, speaks about that, and the biotech’s own efforts to recruit and instill more trust among underserved and medically disenfranchised patients.
Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of...2020-10-2826 min
The Bio ReportGenentech Drug Offers Oral, at-Home Option for SMA PatientsPeople with the rare and fatal genetic disease spinal muscular atrophy in recent years have seen the approval of an antisense therapy as well as a gene therapy. Genentech has now won U.S. Food and Drug Administration approval for Evrysdi, the first oral, at-home treatment for the condition. We spoke to Levi Garraway, chief medical officer and head of global product development at Genentech, about Evrysdi, how it works, and how it fits into the choices physicians and patients have when it comes to treating spinal muscular atrophy.2020-08-1325 min
PhD Transition Report On-DemandWhat To Expect In An Industry R&D Role From Former Genentech Scientist, Elliott Brecht, PhDWhat is the difference between an academic scientist and an industry scientist? Find out in this week’s podcast where Isaiah interviews former senior scientist at Genentech, Elliott Brecht, Ph.D.Here’s a quick rundown of this week’s episode…Join Isaiah as he conducts an informational interview with a fellow Cheeky: Elliott Brecht, PhD.Elliot discusses the role of a scientist in industry research and how it differs from academia.Elliot shares his challenges in transitioning into industry and how to overcome them.From This Week’s Show…Research In Academia V...2020-07-211h 04
RealTalk MSThe Cost of MS Medications, Drug Development, and More: My Conversation with Genentech CEO Alexander HardyConversations about MS almost always get around to the high cost of MS disease-modifying therapies. Joining me on the podcast is the CEO of Genentech, Alexander Hardy. Genentech is a biotech company that many of you know as the manufacturer of Ocrevus, the first approved disease-modifying therapy that treats both relapsing-remitting MS and primary progressive MS. During our wide-ranging conversation, Alexander and I get into the cost of MS prescription medications, the real costs of bringing a new drug to market, racial disparities in clinical trials, inequities in our healthcare system, and more. It's a conversation that you won't want t...2020-07-1432 min
Two Scientists Walk Into a BarS3E04: A Look Into the EyeOur eyes are our windows to the world, but what happens when those windows start to fade or disappear? To understand how the eye works, scientists are combining developments in imaging and genetics to see into the eye and better understand why a disease occurs or whether a treatment is working. Hear from our host Jane Grogan and Menno van Lookeren Campagne, Principal Scientist, Immunology, and get a glimpse into how researchers are combining genetics, imaging and natural history data to better predict eye diseases like age-related macular degeneration and potentially treat them earlier. While Menno van Lookeren Campagne was...2019-08-1033 min
Occupation StationFrom ACPHS to GenentechIn this edition of Occupation Station, Dr. Whitney Kirschbrown, a Scientist in Clinical Pharmacology at Genentech in South San Francisco, California, talks about her role in pharmacokinetic, drug interaction, and exposure-response analyses that help guide prescribing information in the drug label. Dr. Kirschbrown shares some advice for today’s students. She advises student to engage with faculty and staff at ACPHS and be open to the many opportunities they can help guide you toward.2019-02-2610 min
Occupation StationFrom ACPHS to GenentechIn this edition of Occupation Station, Marc Watrous, Senior Vice President of Managed Care and Customer Operations for Genentech, talks about how he entered ACPHS thinking he would ultimately run an independent pharmacy in his hometown. Instead his career path took many interesting detours, eventually landing him in the field of Health Economics. Watrous talks what skills are hot in today’s job market and how his education at ACPHS helped him develop the skills he uses today.2019-02-2611 min
Workplace Innovator Podcast | Enhancing Your Employee Experience | Facility Management | CRE | Digital Workplace TechnologyEp. 31: Designing Neighborhood Work Environments to Liberate the Workforce | Terry Tran & Sara Andersen - GenentechTerry Tran is Associate Director of Work Environment Integration and Sara Andersen is Director of Real Estate Management at Genentech, a member of the Roche Group, one of the world's leading biotechnology companies. Mike Petrusky recently visited Genentech's corporate campus in South San Francisco to talk about workplace strategy and how Terry and Sara collaborate to create a "cohesive and connected workplace" across the campus and the community. Their unique approach is built around "Neighborhood Work Environments" and is designed with physical, technological and social spaces that enable business units to achieve specific outcomes. Terry and Sara believe that...2018-11-0620 min
Behind The AdvisorEp #175: Financial Planning for Genentech Employees - The Career of David Barson My guest today is a great example of how powerful it can be to nail down a niche. David Barson is the founder of Barson Financial Planning, and nearly two years after starting his firm, he has really started focusing on his ideal client profile: Genentech employees. Having started his own career in biotech and worked at the company himself, David is able to connect with current employees in ways most other advisors can’t, making his client relationships that much stronger. In this episode, David shares his experience transitioning into the financial planning world and ultimately ma...2018-10-241h 01Behind The AdvisorEp #175: Financial Planning for Genentech Employees - The Career of David Barson My guest today is a great example of how powerful it can be to nail down a niche. David Barson is the founder of Barson Financial Planning, and nearly two years after starting his firm, he has really started focusing on his ideal client profile: Genentech employees. Having started his own career in biotech and worked at the company himself, David is able to connect with current employees in ways most other advisors can’t, making his client relationships that much stronger. In this episode, David shares his experience transitioning into the financial planning world and ultimately ma...2018-10-241h 01
Two Scientists Walk Into a BarS2E02: Proteins: Seeing is BelievingThe world of proteins is a minuscule and elegant ballet. Recent advances in imaging techniques have given us unprecedented views into this microscopic world, which could help us design better targeted therapies for a wide range of diseases. Learn more from Sarah Hymowitz, Vice President, Protein Sciences at Genentech, about why she has fallen in love with all things protein.2017-10-2527 min
Two Scientists Walk Into a BarS2E01: Connective Tissue: The Hidden MetropolisIf your body was a city, then connective tissue would be the infrastructure tying everything together. It’s a hidden universe that helps many types of cells talk to each other and helps us fight diseases like rheumatoid arthritis or cancer. That’s why Shannon Turley has dedicated her research to uncovering the complexities of connective tissue, from her days as a graduate student shuttling ice boxes of live cells on the train to Principal Scientist of Cancer Immunology at Genentech. Hear more from Shannon on our debut episode of Season 2!2017-09-2827 min
Running Through WallsFrom Genentech to Facebook to Startup: Part TwoPart two of the discussion between former Genentech and Facebook CFO David Ebersman and Venrock’s Bryan Roberts centers on Ebersman’s time at Genentech, where he started working in his 20s and worked up his way up, eventually becoming CFO. He shares anecdotes about working with another executive dynamic duo, Art Levinson and Sue Desmond-Hellmann, and what he learned about problem-solving after working closely with them for several years. Ebersman also discusses Roche’s hostile takeover of Genentech in 2009, and his perspective on financial modeling following the deal. 2017-05-2423 min
Running Through WallsFrom Genentech to Facebook to Startup: Part OneIn the first part of his discussion with Bryan Roberts of Venrock, former Genentech and Facebook CFO David Ebersman shares what he learned about leadership from the dynamic duo of Mark Zuckerberg and Sheryl Sandberg at Facebook, and discusses his experience taking the company public in 2012. Now CEO and founder of Lyra Health, Ebersman discusses how Lyra solves the problem of finding quality care for mental health conditions, and talks about the most surprising aspects of being a startup founder after stints at large companies. 2017-05-1012 min
Two Scientists Walk Into a BarS1E07: Biomarkers and Big DataEach person’s cancer is unique, so trying to match the right treatment to the right person is one of cancer biology’s biggest remaining challenges. In our latest episode, Priti Hegde, Director of Oncology Biomarker Development at Genentech, talks about how big data and advanced technology are guiding the future of personalized cancer immunotherapies.2017-02-2721 min
Two Scientists Walk Into a BarS1E06: Continuing the Fight Against Breast CancerSome types of breast cancer can become “addicted” to estrogen signaling, so treatments that target the estrogen receptor were once thought to be a magic bullet against this disease. But breast cancer is sneaky, and some mutations can allow it to sidestep these types of targeted therapies. In our latest episode, Lori Friedman, Senior Director of Translational Oncology at Genentech, talks about the ways scientists are trying to stay one step ahead of breast cancer.2017-01-1116 min
Two Scientists Walk Into a BarS1E05: The Search for Super AntibioticsBacteria are remarkably fast shape-shifters. As soon as we develop new antibiotics against them, they mutate, leading to drug-resistant strains the world has never seen before. This could mean that one day we end up weaponless against an army of drug-resistant superbugs. But a new generation of “super antibiotics” could hold the key to overcoming this problem. Learn how as we sit down with Rick Brown, Vice President of Immunology and Infectious Diseases at Genentech, in our latest podcast.2016-12-1421 min
Childhood Cancer Talk Radio PodcastsGenentech: Leading the Industry with iPODD, iMATRIX and More with Raphael Rousseau, MD, PhDCCTR interviews Raphael Rousseau MD, PhD,the global franchise head of the innovative pediatric drug development group at Genentech. Considered the founder of the biotech industry, Genentech, a member of the Roche Group, has headquarters in South San Francisco, California. Genentech has been delivering on the promise of biotechnology for over 40 years, and oversees Roche’s pediatric strategy and ensures optimized implementation of pediatric clinical development plans across the company’s oncology portfolio. Dr. Rousseau explains the innovative Pediatric Oncology Development Group and the iMatrix protocol, which pairs medicines with their known molecular targets, regardless of the cancer type. Matching appr...2016-09-2900 min
The Millennial Career PlaybookGenentech's Amanda Valentino interviewed by Debbie Wooldridge & Hy BenderGenentech - The Millennial Career Playbook2015-07-1721 min
Litigation Quality Patent PatentCastThe Examiner Whisperer - Sanofi-Aventis v Genentech In this episode of the Litigation Quality Patents® Podcast, the discussion concerns patent license agreements. Craige outlines key portions of patent license agreements and how to best construct them in order to avoid going through re-litigation on issues of infringement. Listen to the Podcast: EPISODE 11 – The Examiner Whisperer – Sanofi-Aventis v Genentech – May 16 2013 Litigation Quality Patents® Podcasts The Litigation Quality Patents® Podcast, hosted each week by Craige Thompson (a.k.a., “The Examiner Whisperer”) contains substantive discussion designed to keep you current with what’s going on in the world of patents, encompassing everythi...2013-09-2413 min
New Books in the History of ScienceSally Smith Hughes, “Genentech: The Beginnings of Biotech” (University of Chicago Press, 2011)Genentech: The Beginnings of Biotech (University of Chicago Press, 2011) tells many stories of many things. It is the story of a handful of people who figured out how to make recombinant DNA technology into a thriving business. It is the story of the emergence of a new hybrid organism, the entrepreneurial biologist, who lived with one leg in academia and one in corporate research. It is the story of a series of compounds that became big business in the American corporate world: human insulin, human growth hormone, and interferon among them. Drawing on a series of fascinating oral histories...2012-12-031h 03
New Books in Biology and EvolutionSally Smith Hughes, “Genentech: The Beginnings of Biotech” (University of Chicago Press, 2011)Genentech: The Beginnings of Biotech (University of Chicago Press, 2011) tells many stories of many things. It is the story of a handful of people who figured out how to make recombinant DNA technology into a thriving business. It is the story of the emergence of a new hybrid organism, the entrepreneurial biologist, who lived with one leg in academia and one in corporate research. It is the story of a series of compounds that became big business in the American corporate world: human insulin, human growth hormone, and interferon among them. Drawing on a series of fascinating oral histories...2012-12-031h 03
The University of Chicago Press PodcastSally Smith Hughes, “Genentech: The Beginnings of Biotech” (University of Chicago Press, 2011)Genentech: The Beginnings of Biotech (University of Chicago Press, 2011) tells many stories of many things. It is the story of a handful of people who figured out how to make recombinant DNA technology into a thriving business. It is the story of the emergence of a new hybrid organism, the entrepreneurial biologist, who lived with one leg in academia and one in corporate research. It is the story of a series of compounds that became big business in the American corporate world: human insulin, human growth hormone, and interferon among them. Drawing on a series of fascinating oral histories...2012-12-031h 03
CBSGenentech head: New companies make new jobsScott Pelley spoke with Susan Desmond Hellman, the chancellor of UCSF and the head of the drug development company Genentech, on how the United States will create new jobs to fix the struggling economy.2011-10-2603 min
Entrepreneurial Thought Leaders Video SeriesRichard Scheller (Genentech) - Developing Products that Save LivesAs Genentech's Executive Vice President of Research and Early Development, Richard Scheller leads scientists discovering medicines that will significantly impact the lives of patients. In this candid interview, he describes the challenges of his industry, and outlines the required steps for developing products in a heavily regulated environment. Scheller also shares some personal learning curves faced when he elected to leave academic life for a new role in a commercial enterprise.2011-04-2759 min
Entrepreneurial Thought Leaders (ETL)Richard Scheller (Genentech) - Developing Products that Save LivesAs Genentech's Executive Vice President of Research and Early Development, Richard Scheller leads scientists discovering medicines that will significantly impact the lives of patients. In this candid interview, he describes the challenges of his industry, and outlines the required steps for developing products in a heavily regulated environment. Scheller also shares some personal learning curves faced when he elected to leave academic life for a new role in a commercial enterprise.2011-04-271h 00